Global eye health company Johnson & Johnson has rolled out TECNIS Odyssey, its new presbyopia-correcting intraocular lens (PC-IOL) for cataract patients.
The new full visual range IOLs are designed to correct presbyopia during cataract surgery.
It offers patients a continuous full range of vision at every distance in any lighting, making it suitable for reading, driving, or daily activities.
The new TECNIS Odyssey full visual range IOL features proprietary technology that delivers a clearer image, ensuring sharp vision in challenging lighting.
Its design minimises visual disturbances for improved night-time clarity.
According to Johnson & Johnson, the freeform diffractive surface of the lens helps in removing gaps between near, intermediate, and far distances.
In addition, the eye health firm claimed that the latest offering creates lesser halos and glare and offers better image quality than PanOptix IOL both day and night.
Johnson & Johnson vision company group chairman Peter Menziuso said: “TECNIS Odyssey patients have reported outstanding visual outcomes following surgery, which is why we are excited to announce we are expanding the roll-out across the US today.
“Cataract surgery gives patients a once in a lifetime opportunity to improve their sight, and now with this advanced IOL, patients can see clearly at every distance, without the need for glasses.”
TECNIS Odyssey is built on the TECNIS platform. It provides twice the contrast in low light compared to PanOptix, said Johnson & Johnson.
In addition, the eye health technology firm claimed that patients using the new PC-IOL can read 14% smaller print than those with PanOptix IOL. Additionally, 93% of TECNIS Odyssey IOL patients reported no or mild halos, glare, or starbursts a month after surgery.
Under the commercialisation plan, Johnson & Johnson has introduced TECNIS Odyssey IOL Peer Connect. This initiative aims to promote direct discussions about TECNIS Odyssey IOL among healthcare professionals and expert surgeons with early access to the technology.
Furthermore, the IOL has gained regulatory approval in Japan, the European Union (EU), Korea, Singapore, Canada, New Zealand, and Australia.
In early 2024, Johnson & Johnson MedTech introduced its TECNIS PureSee purely refractive presbyopia-correcting lens in Europe, the Middle East, and Africa (EMEA).
